Meningococcal B Vaccine – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of the meningococcal B vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, and the United Kingdom). We report the eligible population recommended to receive the meningococcal B vaccine for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s meningococcal B vaccine forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the meningococcal B vaccine-eligible population over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following meningococcal B vaccine patient populations:
- Meningococcal B vaccine-eligible population.
- The population newly eligible for the meningococcal B vaccine.
Note: Coverage may vary by country.
